BioInvent: Larger Cohort Confirms BI-1808 Efficacy - Redeye

BioInvent: Larger Cohort Confirms BI-1808 Efficacy - Redeye

BioInvent presented the complete Part B cohort of BI-1808 plus pembrolizumab in platinum-resistant ovarian cancer at ESMO 2026. With 34 evaluable patients (25 at ASCO), the objective response remained at 24%. Median PFS was 4.1 months under RECIST and 10.3 months under iRECIST.

Länk till analysen i sin helhet: https://www.redeye.se/research/1189109/bioinvent-larger-cohort-confirms-bi-1808-efficacy?utm_source=finwire&utm_medium=RSS